-
公开(公告)号:US20240003792A1
公开(公告)日:2024-01-04
申请号:US17928177
申请日:2021-04-19
申请人: MDimune Inc.
发明人: Shin Gyu Bae , Seung Wook Oh , Dong Woo Han
IPC分类号: G01N1/40
CPC分类号: G01N1/4077 , G01N2001/4088
摘要: Provided is a method for preparing cell-derived vesicles, and more particularly, a method for preparing cell-derived vesicles using a cell extruder, and a syringe-type cell extruder for effectively preparing cell-derived vesicles. According to the present invention, by using the method for preparing the cell-derived vesicles and the cell extruder, it is possible to prepare cell-derived vesicles in a stable, economical, and mass-producible manner.
-
2.
公开(公告)号:US20240299577A1
公开(公告)日:2024-09-12
申请号:US18275323
申请日:2022-01-28
申请人: MDIMUNE INC.
发明人: Shin Gyu BAE , Seung Wook OH , Jung Eun PARK , Sung Soo PARK , Ye Rim KWON , Hui Chong LAU , Jin Hee PARK
CPC分类号: A61K47/6901 , A61K35/22 , A61K35/28
摘要: The present invention relates to cell-derived vesicles with increased cellular uptake capacity and a method for producing same. The cell-derived vesicles of the present invention are produced by migrating cells to micropores, and exhibit the characteristic of expressing a protein marker that is different from that of exosomes naturally secreted by cells. The cell-derived vesicles with increased cellular uptake capacity, according to the present invention, have remarkably superior cellular uptake capacity as compared to natural exosomes secreted by cells, and thus can be effectively used to deliver various active substances, such as drugs and marker substances, into target cells.
-
公开(公告)号:US20190167587A1
公开(公告)日:2019-06-06
申请号:US16205277
申请日:2018-11-30
申请人: MDIMUNE INC.
发明人: Shin Gyu BAE , Yeon-Mok OH
摘要: Provided herein is a method for treating a pulmonary disease using mesenchymal stem cell-derived artificial nanosomes exhibiting a significantly excellent capability to regenerate alveoli compared to mesenchymal stem cells themselves and natural exosomes derived from human adipose-derived mesenchymal stem cells, wherein the mesenchymal stem cell-derived artificial nanosomes of the present disclosure may be collected through a simple production method using an extruder and an ultracentrifuge, instead of treating mesenchymal stem cells with a separate chemical substance and the potential side effects caused by stem cell therapeutic agents is low.
-
公开(公告)号:US20230257434A1
公开(公告)日:2023-08-17
申请号:US17758825
申请日:2021-01-13
发明人: Shin Gyu Bae , Seung Wook Oh , Joong Hoon Park , Tae Sub Park
IPC分类号: C07K14/47 , C12N5/07 , C07K14/705 , A61K38/17 , A61P21/00
CPC分类号: C07K14/4722 , C12N5/06 , C07K14/70596 , A61K38/17 , A61P21/00 , C12N2510/00
摘要: The present invention relates to cell-derived vesicles comprising target protein Prokineticin receptor 1 (PROKR1), and a therapeutic agent for muscle diseases comprising the same. When applied to myoblasts, the cell-derived vesicles comprising PROKR1 according to the present invention promote muscle differentiation and induce differentiation into myotubes, and can thus be used to prevent or treat muscle diseases and can be widely used in the pharmaceutical industry and the field of health functional foods.
-
公开(公告)号:US10675244B2
公开(公告)日:2020-06-09
申请号:US15959521
申请日:2018-04-23
申请人: MDIMUNE INC.
发明人: Yong Song Gho , Yoon Keun Kim , Su Chul Jang , Oh Youn Kim , Dong-Sic Choi , Yae Jin Yoon
IPC分类号: A61K9/127 , A61K9/50 , A61K45/06 , A61K35/15 , A61K35/545
摘要: The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and/or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.
-
公开(公告)号:US20230383238A1
公开(公告)日:2023-11-30
申请号:US17936027
申请日:2022-09-28
发明人: Davide ZOCCO , Ilaria PASSALACQUA , Shin Gyu BAE , Seung Wook OH , Jeong Eun PARK , Sung-Soo PARK , Hui-Chong LAU
IPC分类号: C12M1/00 , C12N5/0735 , C12M1/26
CPC分类号: C12M47/02 , C12N5/0606 , C12M45/05 , C12M33/14
摘要: The present disclosure provides methods for processing cell-derived vesicles in which the cell-derived vesicles are not purified, prior to contacting with a fluorescent staining dye or an antibody. By utilizing a centrifugal filter, excess staining dye or antibody can be readily removed prior to analysis of one or more characteristics of the cell-derived vesicles. The methods provide rapid and simple processing and analysis, while maintaining a high concentration of cell-derived vesicles.
-
公开(公告)号:US20230065508A1
公开(公告)日:2023-03-02
申请号:US17759268
申请日:2020-09-18
申请人: MDIMUNE INC.
发明人: Dongwoo HAN , Shingyu BAE , Seungwook OH , Yunbeom SIM , Seonjoo LEE
IPC分类号: G01N1/40
摘要: Provided are a cell-extruding device including a membrane module, and a cell-extruding method using the same, wherein a suspension including cells is efficiently dispersed in the membrane module, thus preventing membrane clogging and increasing the usable area of the membrane, and thereby replacing the membrane and carrying out the process are easy, and production efficiency is increased.
-
公开(公告)号:US20240200008A1
公开(公告)日:2024-06-20
申请号:US18593346
申请日:2024-03-01
申请人: MDimune Inc.
发明人: Jik Han JUNG , Byoung Jin KIM , Shin Gyu BAE
摘要: The present invention relates to a method for manufacturing cell-derived vesicles using a depth filter. The present invention has the effect of enabling cell-derived vesicles to be manufactured stably, economically, and in large quantities through a simplified process.
-
公开(公告)号:US20230033198A1
公开(公告)日:2023-02-02
申请号:US17791850
申请日:2020-09-22
申请人: MDimune Inc.
发明人: Se Hee Kim , Ji Eun Lee , Shin Gyu Bae , Ji Hye Le , Jin Hee Park
摘要: A cell extruder of the present invention comprises: a pressure vessel in which a sample is dispensed; a regulator for adjusting a set pressure of nitrogen gas injected into the pressure vessel and then maintaining a constant pressure; an input valve for opening and closing the injection of nitrogen gas into the pressure vessel; an exhaust valve for removing the internal pressure of the pressure vessel; a filter holder which is provided with a membrane filter soaked with a reagent, so that the sample in the pressure vessel is fed through by the nitrogen gas and crushed into extracellular vesicles; and a collection container in which the extruded sample is stored. According to the present invention, pressure can be freely adjusted by the regulator. That is, the flow rate of the membrane according to pressure can be controlled, thus allowing the validation of a biopharmaceutical production method using an extracellular vesicle extruder. In addition, during cell extrusion, a sintered disc can be removed and cells can be extruded by using only a membrane. Vesicles can be produced within a fine pressure adjustment range (at a fine low pressure at which the membrane is not torn) in which no sintered disc is required.
-
10.
公开(公告)号:US20220339102A1
公开(公告)日:2022-10-27
申请号:US17640997
申请日:2020-09-04
发明人: Shin Gyu Bae , Seung Wook OH , Se Hee Kim , Sung Hoon Han , Jeong Seok Choi , Jeong Mi Kim
IPC分类号: A61K9/127 , A61K35/28 , A61K35/50 , A61K35/545 , A61K35/42 , A61K35/34 , A61K35/19 , A61K9/00 , A61K9/48 , A61K9/20 , A61P1/02
摘要: The present invention relates to a salivary gland therapeutic agent using the effects of a cell-derived vesicle of enhancing the proliferation capacity of salivary gland cells, promoting an amylase activity, and enhancing transepithelial resistance. A pharmaceutical composition comprising the cell-derived vesicle according to the present invention has the effects of enhancing the proliferation capacity of salivary gland cells damaged by radiation, promoting amylase activity, increasing transepithelial resistance, enhancing the expression of Aquaporin 5, and increasing the amount of saliva secretion. Therefore, the pharmaceutical composition comprising the cell-derived vesicle of the present invention can be used for preventing and treating salivary gland diseases, and thus can be widely used in the pharmaceutical industry and health functional food field.
-
-
-
-
-
-
-
-
-